Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1816 • ACR Convergence 2023
Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Janis Timsans¹, Jenni Kauppi¹, Hannu Kautiainen² and Markku Kauppi³, ¹Päijät-Häme Central Hospital, Lahti, Finland, ²University of Helsinki, Folkhälsan Research Center, Helsinki, Finland, ³University of Helsinki, Helsinki, Finland
Background/Purpose: Elevated serum uric acid (SUA) level is rather prevalent in the general population, and it is associated with numerous comorbidities and mortality. Etiology of…
Abstract Number: 0753 • ACR Convergence 2023
Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Jeremy Sullivan¹, Anna Ware², Gary Tarasovsky³, Cherish Wilson⁴, Mary Whooley³, Jasvinder Singh⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁴, ¹University of California San Francisco, San Francisco, CA, ²Palo Alto VA, Minneapolis, MN, ³San Francisco VA, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…
Abstract Number: 1909 • ACR Convergence 2023
Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Lena Eder¹ and David Leverenz², ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC
Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…
Abstract Number: 0814 • ACR Convergence 2023
Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial
Joshua Qu¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jefferey Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴University of Nebraska, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…
Abstract Number: 2241 • ACR Convergence 2023
Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielman², Jacques-Eric Gottenberg³, Pierre-Marie Duret², Emmanouil Rampakakis⁴, Mohamed Sharaf⁵, Caren Constantin⁶, vincenza campana⁶ and Laurent Messer⁷, ¹Hôpital de Hautepierre, Strasbourg, France, ²Hôpitaux civils de Colmar, Colmar, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁴JSS Medical Research, Saint-Laurent, QC, Canada, ⁵Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁶Janssen Cilag Medical Affairs, Issy les Moulineaux, France, ⁷Laboratoire Interdisciplinaire en études culturelles (LinCS), Strasbourg, France
Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Jingyi Zhang¹, Ted R Mikuls³, Brian LaMoreaux⁴, Lissa Padnick-Silver⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴Horizon Therapeutics, Deerfield, IL
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…
Abstract Number: 1104 • ACR Convergence 2023
Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial
Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY
Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…
Abstract Number: 1105 • ACR Convergence 2023
Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Jinseok kim, Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea
Background/Purpose: Many studies have reported that gout and hyperuricemia are associated with an increase in all-cause mortality and cardiovascular mortality.Increased vascular stiffness is closely related…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 1206 • ACR Convergence 2022
Association Between Different Alcoholic Beverages and Serum Urate Level: A Cross-Sectional Study Using Large Medical Checkup Data
Sho Fukui¹, Masato Okada², Mahbubur Rahman³, Takehiro Nakai², Hiromichi Tamaki², Hiroki Matsui⁴, Atsushi Shiraishi⁵, Mitsumasa Kishimoto⁶, Hiroshi Hasegawa⁷, Takeaki Matsuda⁷ and Kazuki Yoshida⁸, ¹Kyorin University Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Tokyo, Japan, ³Graduate School of Public Health, St. Luke’s International University, Tokyo, Japan, ⁴Clinical Research Support Office, Kameda Medical Center, Kamogawa, Japan, ⁵Emergency and Trauma Center, Kameda Medical Center, Kamogawa, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷Kyorin University, Tokyo, Japan, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Alcohol consumption is associated with increased serum urate levels. However, data regarding the differences in the extent of the association between various types of…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1579 • ACR Convergence 2022
The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
Abstract Number: 1583 • ACR Convergence 2022
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in the management of gout, involving titration of urate lowering therapy (ULT) to a serum urate (SU) goal…
Abstract Number: 1678 • ACR Convergence 2022
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
Tony Merriman¹, Hirotaka Matsuo², Riku Takei³, Megan Leask³, Ruth Topless¹, Yuya Shirai⁴, Zhiqiang Li⁵, Murray Cadzow¹, Richard Reynolds³, kenneth saag³, Tayaza Fadason⁶, Justin O'Sullivan⁶, Nicola Dalbeth⁶, Lisa Stamp⁷, Abhishek Abhishek⁸, Michael Doherty⁸, Edward Roddy⁹, Lennart Jacobsson¹⁰, Meliha Kapetanovic¹¹, Mariano Andrès¹², Fernando Perez-Ruiz¹³, Rosa Torres Jimenez¹⁴, Timothy Radstake¹⁵, Timothy Jansen¹⁶, Matthijs Janssen¹⁷, Leo Joosten¹⁸, Tania Octavia Crisan¹⁹, Tom Huizinga²⁰, Frederic LIOTE²¹, Pascal Richette²², Thomas Bardin²³, Tristan Pascart²⁴, Geraldine McCarthy²⁵, Blanka Stiburkova²⁶, Anne Tausche²⁷, Till Uhlig²⁸, Veronique Vitart²⁹, Philip Riches²⁹, Stuart Ralston²⁹, Thomas MacDonald³⁰, Akiyoshi Nakayama², Masahiro Nakatochi³¹, Kimiyoshi Ichida³², Tappei Takada³³, Chaeyoung Lee³⁴, Matthew Brown³⁵, Philip Robinson³⁶, Catherine Hill³⁷, Hyon Choi³⁸, Nicholas Sumpter³, Marilyn Merriman³, Amanda Phipps-Green¹, Wenhua Wei¹, Sally McCormick¹, Olle Melander³⁹, René Toes²⁰, Hang-Korng Ea²¹, Fina Kurreeman²⁰, Laura Helbert²⁵, Thibaud Boutin²⁹, Nariyoshi Shinomiya², Linda Bradbury⁴⁰, Russell Buchanan⁴¹, Susan Lester³⁷, Malcolm Smith⁴², Maureen Rischmueller⁴³, On behalf of Japan Gout Genomics Consortium (J-Gout)⁴⁴, On behalf of Japan Multi-Instl Collab Cohort Study (J-MICC)⁴⁵, Eli Stahl⁴⁶, Jeff Miner⁴⁷, Daniel Solomon⁴⁸, Jing Cui⁴⁸, Kathleen Giacomini⁴⁹, Deanna Brackman⁴⁹, Eric Jorgenson⁵⁰, On behalf of 23andMe Research Team⁵¹, Suyash Shringapure⁵¹, Alexander So⁵², Yukinori Okada⁴, Changgui Li⁵, Yongyong Shi⁵³ and Tanya Major¹, ¹University of Otago, Dunedin, New Zealand, ²National Defense Medical College, Saitama, Japan, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Osaka University, Suita, Osaka, Japan, ⁵The Affiliated Hospital of Qingdao University, Qingdao, China, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸University of Nottingham, Nottingham, United Kingdom, ⁹Keele University, Keele, United Kingdom, ¹⁰Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ¹¹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden, ¹²Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ¹³University of the Basque Country, Barakaldo, Spain, ¹⁴La Paz University Hospital, Madrid, Spain, ¹⁵University Medical College Uthrecht, Utrecht, Netherlands, ¹⁶VieCuri Medical Centre, Venlo, Netherlands, ¹⁷Rijnstate Hospital, Bennekom, Netherlands, ¹⁸Radboudumc, Nijmegen, Netherlands, ¹⁹University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Cluj-Napoca, Romania, ²⁰Leiden University Medical Center, Leiden, Netherlands, ²¹University of Paris, Paris, France, ²²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²³Hôpital Lariboisiere, Paris, France, ²⁴Lille Catholic University, Lille, France, ²⁵Mater Misericordiae University Hospital, Dublin, Ireland, ²⁶Institute of Rheumatology, Prague, Czech Republic, ²⁷University Clinic 'Carl Gustav Carus' at the Technical University, Dresden, Germany, ²⁸Diakonhjemmet Hospital, Oslo, Norway, ²⁹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³⁰University of Dundee, Dundee, United Kingdom, ³¹Nagoya University Hospital, Nagoya, Japan, ³²Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ³³University of Tokyo Hospital, Tokyo, Japan, ³⁴Soongsil University, Seoul, Republic of Korea, ³⁵Genomics England, London, United Kingdom, ³⁶University of Queensland, Brisbane, Australia, ³⁷The Queen Elizabeth Hospital, Adelaide, Australia, ³⁸Massachusetts General Hospital, Lexington, MA, ³⁹Lund University, Malmö, Sweden, ⁴⁰Gold Coast University Hospital, Brisbane, Australia, ⁴¹Austin Health, Heidelberg, Australia, ⁴²Flinders Medical Centre, Adelaide, Australia, ⁴³RheumatologySA, Adelaide, Australia, ⁴⁴Japan Gout Genomics Consortium (J-Gout), Saitama, Japan, ⁴⁵Japan Multi-Institutional Collaborative Cohort Study (J-MICC), Nagoya, Japan, ⁴⁶Regeneron, New York, NY, ⁴⁷ViscientBio, San Diego, CA, ⁴⁸Brigham and Women's Hospital, Boston, MA, ⁴⁹University of California San Francisco, San Francisco, CA, ⁵⁰Kaiser Permanente, San Francisco, CA, ⁵¹23andMe, Inc., Sunnyvale, CA, ⁵²University of Lausanne, Lausanne, Switzerland, ⁵³Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Genome-wide association studies (GWAS) in gout have been relatively small (≤13,179 people with gout) and have provided little insight into the progression from hyperuricemia…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].